RBC Europe’s Liminal BioSciences Inc. Common Shares LMNL Stock Holding History

RBC Europe’s Portfolio LMNL Stock Details LMNL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$0	Hold	23	–	–	﹤0.01%	667
2022 Q1	$0	Hold	23	–	–	﹤0.01%	675
2021 Q4	$0	Hold	23	–	–	﹤0.01%	1221
2021 Q3	$541	Hold	23	–	–	﹤0.01%	1194
2021 Q2	$910	Hold	23	–	–	﹤0.01%	1178
2021 Q1	$966	Hold	23	–	–	﹤0.01%	1127
2020 Q4	$983	Hold	23	–	–	﹤0.01%	1090
2020 Q3	$2.6K	Hold	23	–	–	﹤0.01%	966
2020 Q2	$2.53K	Hold	23	–	–	﹤0.01%	935
2020 Q1	$1.56K	Hold	23	–	–	﹤0.01%	931
2019 Q4	$1.96K	Buy	+23	New	+$1.55K	﹤0.01%	963

Other funds holding LMNL

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RBC Europe's LMNL Position: Q2 2022 in Review

RBC Europe held its Liminal BioSciences Inc. Common Shares (LMNL) position steady in Q2 2022 at 23 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #667.

RBC Europe first reported a position in LMNL in Q4 2019 and has held it in 11 quarters since. The position peaked at $2.6K in Q3 2020. 19 funds tracked by Wall St. Rank hold LMNL as of Q2 2022.

RBC Europe held 23 shares of Liminal BioSciences Inc. Common Shares worth $0 as of Q2 2022.
RBC Europe left its Liminal BioSciences Inc. Common Shares share count unchanged in Q2 2022.
Liminal BioSciences Inc. Common Shares made up ﹤0.01% of RBC Europe's portfolio in Q2 2022, its #667 holding.
RBC Europe first reported a position in Liminal BioSciences Inc. Common Shares in Q4 2019 and has held it in 11 quarters since.
RBC Europe's Liminal BioSciences Inc. Common Shares position peaked at $2.6K in Q3 2020.
19 funds tracked by Wall St. Rank held Liminal BioSciences Inc. Common Shares as of Q2 2022.

Based on RBC Europe's 13F filing for Q2 2022, filed 14 Nov 2022.